Shugeng Gao

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, National Cancer Center, National Clinical Research · ORCID：0000-0003-4211-552X

发表论文 190 篇 · 总被引 6825 次 · h-index 39

代表论文

• Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma (2024 · Nature Communications · 被引 69)
• Treatment patterns and clinical outcomes of patients with resectable non–small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World) (2024 · Journal of Thoracic and Cardiovascular Surgery · 被引 32)
• OA13.03 Perioperative Durvalumab for Resectable NSCLC (R-NSCLC): Updated Outcomes from the Phase 3 AEGEAN Trial (2024 · Journal of Thoracic Oncology · 被引 26)
• Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (2025 · Journal of Thoracic Oncology · 被引 24)
• Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial (2024 · Gastric Cancer · 被引 22)
• KLF12 interacts with TRIM27 to affect cisplatin resistance and cancer metastasis in esophageal squamous cell carcinoma by regulating L1CAM expression (2024 · Drug Resistance Updates · 被引 16)